Environmental

KRYS appears stronger than many biotech peers on resource efficiency because R&D intensity is high while leverage remains minimal, limiting balance-sheet pressure from environmental compliance costs.

The company’s low debt-to-equity ratio supports flexibility for future sustainability investments, whereas more leveraged peers face tighter capital allocation constraints and higher refinancing risk.

No direct emissions, energy, or waste disclosures were provided, so the score reflects a relative capital-efficiency advantage rather than verified operational environmental leadership.

Compared with larger pharmaceutical peers, KRYS likely faces a smaller physical footprint and simpler manufacturing exposure, which can reduce environmental permitting and remediation complexity.

Social

KRYS’s elevated R&D spending relative to revenue suggests sustained investment in patient-focused innovation, which is generally more supportive of long-term social value than peers with lower research intensity.

Stock-based compensation remains meaningful, but the ratio is not unusually high versus growth-oriented biotech peers, limiting dilution-related employee and shareholder alignment concerns.

As a rare-disease company, KRYS likely operates in a patient population where access and clinical trust are material, and its research model supports that social license better than peers with weaker pipelines.

No workforce, safety, or community metrics were provided, so the assessment is anchored on capital allocation signals that indirectly support social positioning versus peers.

Governance

KRYS’s very low debt-to-equity ratio indicates conservative financing, which typically reduces creditor influence and governance complexity relative to more levered peers.

The company’s negative net debt-to-EBITDA position suggests excess liquidity, giving management more flexibility and lowering near-term covenant or refinancing governance pressure.

Stock-based compensation at roughly 9.4% of revenue is material, but it remains within a range often seen in biotech, so governance concerns are present but not structurally worse than peers.

No board, audit, or controversy data were provided, so the score reflects a comparatively disciplined capital structure rather than confirmed superior governance practices.

Overall Score

KRYS screens as a strong ESG relative to peers, led by conservative capital structure and research-intensive operations, with limited disclosed ESG downside.

Score Driver: Conservative Balance Sheet And Research-Intensive Operating Model Versus Peers